Vericel (VCEL) Hits New 1-Year High at $17.95

Vericel Corp (NASDAQ:VCEL) shares hit a new 52-week high on Monday . The company traded as high as $17.95 and last traded at $17.81, with a volume of 13383 shares changing hands. The stock had previously closed at $17.58.

VCEL has been the topic of a number of research analyst reports. Needham & Company LLC reduced their target price on Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, August 8th. BTIG Research reiterated a “buy” rating and issued a $17.00 target price on shares of Vericel in a report on Tuesday, August 7th. Finally, BidaskClub upgraded Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $16.75.

The firm has a market cap of $762.05 million, a price-to-earnings ratio of -36.88 and a beta of 3.46. The company has a debt-to-equity ratio of 0.14, a current ratio of 7.96 and a quick ratio of 7.71.

Vericel (NASDAQ:VCEL) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.09. Vericel had a negative return on equity of 17.39% and a negative net margin of 15.80%. The firm had revenue of $22.50 million for the quarter, compared to analysts’ expectations of $18.14 million. The business’s revenue was up 57.3% compared to the same quarter last year. As a group, research analysts expect that Vericel Corp will post -0.23 earnings per share for the current fiscal year.

In other Vericel news, Director Steven C. Gilman sold 9,000 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $12.03, for a total value of $108,270.00. Following the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at $108,270. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dominick Colangelo sold 75,000 shares of the firm’s stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $15.02, for a total value of $1,126,500.00. The disclosure for this sale can be found here. Insiders sold 179,000 shares of company stock worth $2,617,770 over the last three months. 4.70% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in VCEL. Capital Fund Management S.A. purchased a new position in Vericel in the second quarter valued at about $104,000. Quantitative Systematic Strategies LLC purchased a new position in Vericel in the second quarter valued at about $108,000. Pacer Advisors Inc. purchased a new position in Vericel in the third quarter valued at about $112,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Vericel in the second quarter valued at about $116,000. Finally, Commonwealth Equity Services LLC purchased a new position in Vericel in the second quarter valued at about $123,000. 79.31% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2018/12/03/vericel-vcel-hits-new-1-year-high-at-17-95.html.

About Vericel (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Further Reading: What is dollar cost averaging (DCA)?

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit